Compare Huntington Ingalls Industries Inc (HII) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Ingalls Industries Inc vs Organon & Co. Common Stock — how do they compare? Huntington Ingalls Industries Inc trades at $264.2 (market cap $10.16B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Huntington Ingalls Industries Inc is far larger — about 2.8× Organon & Co. Common Stock's market cap, and Huntington Ingalls Industries Inc pays the higher dividend (2.14%). Which is the better fit depends on your goals — on Pluang, investors hold Huntington Ingalls Industries Inc for 30 Days and Organon & Co. Common Stock for 0 Days on average.
| HII | OGN | |
|---|---|---|
Market Cap | $10.16B | $3.62B |
Volume | 503,029 | 2,892,999 |
Sector | Industrials | Health |
52-Week High | $453.73 | $13.81 |
52-Week Low | $257.05 | $5.70 |
Typical Hold Time | 30 Days | 0 Days |
Enterprise Value | $13.08B | $11.04B |
Dividend Yield | 2.14% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HII trades at $257.84, down 2.34% today, amid a bearish technical signal but strong fundamentals. The company demonstrates consistent earnings beats, with Q2 2026 EPS of $5.27 exceeding expectations by 39%. Recent contract wins, including a $5.1 billion aircraft carrier overhaul and 10 unmanned vessel orders, bolster its $57.3 billion backlog. Valuation metrics appear attractive with a P/E of 15.36 and P/S of 0.77.
The investment case balances strong defense sector positioning against near-term technical weakness. Analyst consensus targets $357.00, implying 38% upside, with 41% buy ratings. Key risks include execution on large contracts and defense budget fluctuations. The current price near support at $258 presents a potential entry point for long-term investors.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
